Analysis finds semaglutide and tirzepatide match at some doses in type 2 diabetes

A pooled analysis of 23 phase III trials finds that semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) produce comparable weight loss at certain matched doses in people with type 2 diabetes ^[1][2]. The result narrows a gap that has been consistently wide in obesity trials that did not include people with diabetes ^[2].

The analysis, published in the journal Diabetes Therapy, combined arm-level results from 48 treatment arms and 16,524 participants with type 2 diabetes ^[1][2]. Fifteen trials contributed semaglutide data at weekly doses from 0.5 to 7.2 milligrams, and eight contributed tirzepatide data at weekly doses of 5, 10 and 15 milligrams ^[1][2]. Treatment lasted 26 to 104 weeks. Across trials, participants averaged about 55 years old, a baseline HbA1c near 7.8 percent, and a body mass index between 33 and 34 ^[1][2]. The work was led by Carlos E. Builes-Montaño of Hospital Pablo Tobón Uribe and the University of Antioquia in Medellín, Colombia, with coauthors from Novo Nordisk, the maker of semaglutide ^[1][2].

Researchers modeled each drug's dose-response curve and then tested whether specific dose pairs predicted weight changes within 2 percentage points of each other, a margin they defined as clinical equivalence ^[1][2]. Semaglutide produced a median weight loss of roughly 5 to 6 percent at 1.0 milligram per week, about 10 percent at 2.4 milligrams, and further reductions at 7.2 milligrams ^[1][2]. Tirzepatide's effect rose steadily across its 5-to-15-milligram range, with the largest reductions at the highest dose ^[1][2].

Two pairings met the equivalence threshold: semaglutide 2.4 milligrams against tirzepatide 10 milligrams, at a 99.4 percent probability of equivalence, and semaglutide 7.2 milligrams against tirzepatide 15 milligrams, at 94.8 percent ^[1][2]. Pairing semaglutide 1.0 milligram with tirzepatide 10 or 15 milligrams produced near-zero equivalence probabilities, meaning the low semaglutide dose could not match higher-dose tirzepatide ^[1][2]. The authors concluded that equivalence tracked dose rather than which molecule was used, while cautioning that this should not be read as blanket interchangeability, since tolerability, patient preference and prior treatment response still shape treatment selection ^[1][2].

Modeling of treatment intensification found that for patients on semaglutide 1.0 milligram, raising the dose to 2.4 milligrams carried a higher probability of adding at least 2 percentage points of weight loss than switching to tirzepatide 5 milligrams ^[2]. The pattern reversed at higher doses: among patients already on tirzepatide 10 milligrams, switching to semaglutide 7.2 milligrams produced a larger expected added benefit than moving up to tirzepatide 15 milligrams ^[2].

The authors list several limits. The analysis used aggregated trial-level data rather than individual patient records, so it could not adjust for other conditions, medications or background diabetes treatments ^[2]. Estimates for semaglutide 7.2 milligrams rest on a single trial and are described as exploratory ^[2]. Side effects and discontinuation rates were extracted but not formally modeled because reporting differed across trials ^[2]. The analysis covered weight loss only, leaving blood sugar control, heart outcomes and safety outside its scope ^[2]. It also applies to people with type 2 diabetes; the only head-to-head trial of the two drugs, SURMOUNT-5, was conducted in people with obesity who did not have diabetes and compared maximum tolerated doses rather than the full dose range ^[2].

Why it matters for patients

Switches between these drugs happen for reasons including supply shortages, insurance coverage, cost and side effects ^[1][2]. Before this analysis, people facing a switch, and the clinicians and insurers deciding what to cover, had no quantitative guide to which dose of the other drug would preserve weight-loss results in type 2 diabetes, because no head-to-head trial had compared the drugs across a full dose range in that population ^[2].

The analysis offers one. It identifies two dose pairings that appear roughly equal for weight loss, and it shows that a low semaglutide dose does not match higher-dose tirzepatide ^[1][2]. Equally important, the equivalence measured here covers weight loss alone: how the two drugs compare on side effects, blood sugar and heart risk was not modeled, and that gap has not been closed by this work ^[2]. The findings also do not extend to people without diabetes ^[2]. Whether insurers change formulary or step-therapy rules in response has not been reported.